TY - JOUR
T1 - Questionnaire survey on the prescription of renal replacement therapy for acute phase patients on maintenance dialysis who developed cerebrovascular disease
AU - Akiu, Maho
AU - Yamamoto, Tae
AU - Fujikura, Emi
AU - Okamoto, Koji
AU - Nakagawa, Atsuhiro
AU - Yoshida, Mai
AU - Nakamichi, Takashi
AU - Fukushi, Taro
AU - Nagasawa, Tasuku
AU - Oe, Yuji
AU - Nakayama, Masaaki
AU - Sato, Hiroshi
AU - Tominaga, Teiji
AU - Ito, Sadayoshi
AU - Harigae, Hideo
AU - Miyazaki, Mariko
N1 - Funding Information:
The authors thank all the facilities who responded to this questionnaire survey. The authors received a subsidy for this study from the Public Interest Foundation Corporation, Miyagi Kidney Association.
Publisher Copyright:
© 2020, Japanese Society of Nephrology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: There is limited information about acute phase renal replacement therapy (RRT) for maintenance hemodialysis patients after the onset of cerebrovascular disease. This study aimed to investigate which modality of renal replacement therapy is currently selected in practice. Methods: We conducted a mail-based survey in 317 dialysis facilities that were certified by three academic societies that focus on dialysis, neurology, and neurosurgery in Japan. Results: We received responses from 103 facilities (32.5%). In cases of cerebral infarction (CI) and intracerebral hemorrhage (ICH), more than 80% of the facilities selected only intermittent RRT, and 22.3% (CI)/8.7% (ICH) of the facilities selected intermittent HD which is the same setting in normal conditions. Although continuous hemodiafiltration and peritoneal dialysis are recommended in the Japanese guidelines, these were selected in only a few facilities: 16.5% and 0% in CI, 16.5% and 1% in ICH, respectively. RRT on the day of onset tended to be avoided, irrespective of the duration following the last HD session. Furthermore, physicians preferred to modify anticoagulants and reduce dialysis performance in the acute phase. Conclusion: This questionnaire survey uncovered a gap between guidelines and actual practice, even in hospitals accredited as educational facility, which is a novel and important finding. Further studies with larger sample sizes are needed to determine the optimal modality of RRT for the acute phase of cerebrovascular disease.
AB - Background: There is limited information about acute phase renal replacement therapy (RRT) for maintenance hemodialysis patients after the onset of cerebrovascular disease. This study aimed to investigate which modality of renal replacement therapy is currently selected in practice. Methods: We conducted a mail-based survey in 317 dialysis facilities that were certified by three academic societies that focus on dialysis, neurology, and neurosurgery in Japan. Results: We received responses from 103 facilities (32.5%). In cases of cerebral infarction (CI) and intracerebral hemorrhage (ICH), more than 80% of the facilities selected only intermittent RRT, and 22.3% (CI)/8.7% (ICH) of the facilities selected intermittent HD which is the same setting in normal conditions. Although continuous hemodiafiltration and peritoneal dialysis are recommended in the Japanese guidelines, these were selected in only a few facilities: 16.5% and 0% in CI, 16.5% and 1% in ICH, respectively. RRT on the day of onset tended to be avoided, irrespective of the duration following the last HD session. Furthermore, physicians preferred to modify anticoagulants and reduce dialysis performance in the acute phase. Conclusion: This questionnaire survey uncovered a gap between guidelines and actual practice, even in hospitals accredited as educational facility, which is a novel and important finding. Further studies with larger sample sizes are needed to determine the optimal modality of RRT for the acute phase of cerebrovascular disease.
KW - Cerebrovascular disease
KW - Continuous renal replacement therapy
KW - Maintenance hemodialysis
KW - Questionnaire
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85085388513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085388513&partnerID=8YFLogxK
U2 - 10.1007/s10157-020-01905-9
DO - 10.1007/s10157-020-01905-9
M3 - Article
C2 - 32451751
AN - SCOPUS:85085388513
SN - 1342-1751
VL - 24
SP - 821
EP - 828
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 9
ER -